Welcome! You are visiting the MyeloRx web site.

Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
Summary
 
MyeloRx is a development stage company with compounds derived from a natural product

The principals have extensive pharmaceutical experience in both large and small companies

All compounds are covered by in-licensed or internally developed patent estates

Lead compounds have been identified for acute myeloid leukemia and immune-based diseases


 
 
 This web site was last modified on Wednesday, April 23, 2008